What Daflon 500 Treats: Main Uses and Benefits

The medication's primary therapeutic role is to offer symptomatic relief across clinical domains where symptoms are driven by compromised venous and microcirculatory health. It is relevant in clinical settings marked by increased discomfort associated with chronic vascular conditions.

It is commonly used to help manage the functional symptoms of Chronic Venous Insufficiency (CVI) and is applied across conditions presenting with acute hemorrhoidal episodes. This means the medicine is relevant for easing symptoms like the sensation of heavy legs, persistent pain, aching, and nocturnal leg cramps, as well as the acute manifestations of hemorrhoids such as bleeding and local irritation. The medication supports the patient during difficult episodes by easing distress related to inflammatory or irritative states.

“The primary benefit is often experienced as an improvement in day-to-day comfort, helping patients cope more steadily with symptom fluctuations.”

This supportive therapeutic benefit provides relief that assists with maintaining functional stability.

---

Quick Fact: Relief for Venous and Hemorrhoidal Symptoms

Symptom Domain	Key Symptom Clusters	Primary Benefit Focus
Chronic Venous Disease	Heavy legs, pain, nocturnal cramps, swelling (edema)	Contributes to easing the overall symptom load and discomfort.
Acute Hemorrhoidal Episodes	Acute pain, bleeding, local irritation, discomfort	Applied to help manage the disruptive symptoms during flare-ups.
Advanced CVD	Venous leg ulcers (adjunctive use)	Relevant when supportive symptom management is appropriate for healing.

Regulatory References

1. DailyMed Official Product Information for VASCULERA

The eligibility for using Daflon 500 is governed by specific regulatory criteria documented in official product information. This profile is defined by age, allergy status, and physiological state.

Contraindications and Restrictions

The primary absolute rule for non-use is Hypersensitivity. The medicine is contraindicated in patients with a known allergy to the active substance, Micronized Purified Flavonoid Fraction (MPFF), or to any of the tablet's excipients.

Population Group	Regulatory Status
Adults (18+ years)	Established Use (Permitted for labeled indications)
Children and Adolescents (Under 18)	Use Not Established (Safety and efficacy are lacking)

Use is also subject to restrictions based on reproductive status. During pregnancy, it is preferable to avoid use as a precautionary measure due to limited human data. For breast-feeding women, the medicine is not recommended or inadvisable because it is unknown if the active substance is excreted into human milk.

There are no specific dose adjustments or restrictions explicitly documented in the official labeling for patients with renal or hepatic impairment.

Interactions with other medicines and products

The official interaction profile for Daflon 500 (Micronized Purified Flavonoid Fraction) is formally defined by the status of clinical and post-marketing data documented in government-approved regulatory information. This official documentation states that no formal interaction studies have been performed to systematically assess the drug’s potential to interact with other medicinal products.

As a result, the regulatory labeling does not provide specific restrictions or detailed interaction cautions. The official profile does not include information on:

• Pharmacokinetic Interactions: The label does not define interactions related to drug transport proteins or metabolic enzymes, such as the Cytochrome P450 system.
• Pharmacodynamic Interactions: No official documentation is available describing additive or synergistic effects with other substances.
• Administration Constraints: There are no mandatory requirements in the prescribing information for separating the administration time of this medicine from any co-administered products.

The overall interaction structure is characterized by the explicit regulatory statement that no clinically relevant drug interaction has been reported to date from post-marketing experience on the product. This means the official documentation does not list specifically contraindicated combinations, interacting medicinal product categories, or dose adjustment requirements tied to established interaction risk.

The mechanism of the Micronized Purified Flavonoid Fraction (MPFF) is multi-level, combining vascular tone enhancement with microcirculatory modulation and anti-inflammatory activity.

Modulating Venous Tone and Capacitance

This domain covers the primary venotonic mechanism, where the MPFF potentiates noradrenergic signaling within the venous smooth muscle layer. This interaction enhances the effect of naturally occurring norepinephrine, which is the physiological signal for vein contraction, resulting in an increase in venous tone that reduces vessel capacitance. This action influences fluid dynamics by increasing venous blood return and supports the regulation of peripheral vascular resistance.

️ Modulating Capillary Permeability and Barrier Function

The mechanism extends to the microcirculation, focusing on reducing capillary hyperpermeability and stabilizing the endothelial barrier. By downregulating adhesion molecules (like ICAM-1), the MPFF inhibits leukocyte adherence and migration, thereby reducing inflammatory drivers of vessel wall damage. This reduction in filtration rate is the physiological mechanism that influences the accumulation of extravascular fluid.

Synergistic Mechanism and Multi-Targeted Modulation

The fixed combination of Diosmin (90%) and Hesperidin (10%) works in a coordinated, complementary fashion. While Diosmin drives the venotonic effect, Hesperidin contributes significant antioxidant and anti-inflammatory support. This integrated mechanism provides multi-level modulation of vascular responses, supporting the long-term structural integrity of the small vessels and leading to a coordinated physiological adjustment across the microvascular network.

How to Use Daflon 500: Official Administration Guidelines

Daflon 500 mg is administered exclusively via the oral route as a film-coated tablet, which is the only official dosage form available. Each tablet contains 500 mg of the Micronized Purified Flavonoid Fraction (MPFF), intended to be swallowed whole with a glass of water. The medication is structured for use in two distinct, high-level patterns, each with its own official dosing schedule.

---

Official Dosing Regimens

Administration is dictated by the clinical scenario, specifying a different tablet count and frequency for chronic versus acute conditions.

Clinical Scenario	Dosing Instructions	Total Daily Dose	Use Pattern
Chronic Venous Insufficiency	1 tablet taken twice daily (midday and evening).	1000 mg MPFF	Continuous, maintenance use
Acute Hemorrhoidal Attack (Initial Phase)	6 tablets daily for the first 4 days.	3000 mg MPFF	Short-term, high-intensity
Acute Hemorrhoidal Attack (Step-Down Phase)	4 tablets daily for the next 3 days.	2000 mg MPFF	Short-term, fixed duration

---

Administration Requirements

For proper administration, the tablets must be taken at meal times (midday and evening are typically specified). The treatment for acute hemorrhoidal episodes is mandated to be short-term, following the structured 7-day course outlined in the regimen, and is not intended for long-term self-management of acute episodes. Safety and efficacy for the medication have not been established for use in children and adolescents under 18 years of age.

Evidence for Chronic Venous Disease and Insufficiency

Research exploring symptoms in Chronic Venous Disease (CVD) has relied extensively on Randomized Controlled Trials (RCTs) and their Systematic Reviews. These studies monitor patient-reported outcomes describing discomfort, such as leg pain, heaviness, and night-time cramps, alongside objective measures like changes in leg swelling (edema).

Research explored patient populations across the full range of CVD severity, including advanced conditions like venous leg ulcers, where the medicine was studied as an adjunctive component. The evidence quality for symptomatic change varies across studies, and some high-level reviews noted high data variability (heterogeneity) among earlier clinical research.

---

Evidence for Acute Hemorrhoidal Episodes

Research focuses on short-term, placebo-controlled trials conducted during periods of heightened symptom activity characteristic of hemorrhoidal flare-ups. The primary outcomes examined are acute changes related to physical discomfort, such as anal pain, bleeding, and local irritation. Research describes patterns observed in the studies related to the timeframe for the evolution of these acute symptoms.

The key limitation is that follow-up durations were limited, focusing on the short-term course of the acute episode, often only seven to fourteen days.

---

Long-Term Outcomes and Research Gaps

Studies examining chronic conditions typically followed patients for intermediate periods, often between one and six months. However, a universal limitation across the evidence base is that long-term effects are not fully established in the research. There is limited information for long-term outcomes regarding the durability of any observed response for years.

A primary research gap is the uncertainty regarding the long-term role in chronic management of hemorrhoidal disease. Furthermore, comparative evidence is lacking for some patient subgroups, such as older adults with multiple comorbidities.

Common questions about Daflon 500 (FAQ)

Q: How long is Daflon 500 typically recommended for long-term venous issues?

A: The official duration for treating long-term venous issues is not fixed in regulatory documents. However, official information typically notes a limit, stating that consultation with a healthcare professional is generally appropriate for use extending beyond two to three months to review the need for continued use.

Q: Is Daflon 500 use restricted for people with pre-existing kidney conditions?

A: Official product labeling notes that use requires caution in individuals with pre-existing kidney or liver impairment. This caution is noted because formal data on the drug's use and effects in these specific patient populations is currently limited.

Q: What is the usual time frame for seeing improvement in chronic venous disease symptoms?

A: Clinical data summarized in official documents indicates that a reduction in symptoms of chronic venous disease, such as feelings of heaviness, leg pain, and swelling, was observed in studies after one month of continuous use.

Q: How soon after starting Daflon 500 can a patient expect to feel relief from hemorrhoid symptoms?

A: Studies examining acute hemorrhoidal episodes indicate that a reduction in symptoms was observed as early as two days after beginning the high-intensity treatment regimen. Furthermore, official data noted that cessation of bleeding was reported for 80% of patients by the third day of treatment.

Q: Can Daflon 500 affect a person's ability to drive or operate machinery?

A: According to official product labeling, Daflon 500 has no or only a negligible influence on a person’s ability to drive or operate machinery. The rare side effect of dizziness is listed in the safety information.

Q: Is it possible to have an allergic reaction to the flavonoid components like diosmin?

A: The medicine is formally contraindicated (should not be used) in anyone with a known hypersensitivity to the active substance, the Micronized Purified Flavonoid Fraction. This includes potential allergic reactions to its main components, which are diosmin and hesperidin.

Q: What steps should be taken if side effects like nausea or stomach pain persist?

A: If a patient experiences any side effects, including common gastrointestinal symptoms like nausea or stomach pain, and they persist, official guidance states that consultation with a doctor or pharmacist is recommended. Regulatory requirements also encourage the reporting of suspected adverse reactions.

Q: If hemorrhoid symptoms do not improve after 15 days, what does official guidance recommend?

A: The official guidance states that if symptoms of an acute hemorrhoidal attack do not subside or improve within 15 days, medical consultation is the recommended next step. The regulatory basis for this suggests that a proctological examination may be appropriate at that point to review the treatment.

Q: Is Daflon 500 considered a cure for varicose veins or only a symptom management treatment?

A: Official product labeling indicates that the medicine is approved for the symptomatic treatment of venous circulation disorders, such as varicose veins, and acute hemorrhoidal attacks. It is classified as a venotonic agent intended to help manage symptoms.

Q: Can Daflon 500 be used for general pain in the legs not caused by varicose veins?

A: The approved indication for use is specifically for symptoms like heavy legs, pain, and restless legs that are directly related to underlying venolymphatic insufficiency. The product label does not include general leg pain that is not associated with this circulatory condition.

Q: Does the drug help with general leg swelling or edema?

A: Yes, the medicine is officially indicated for the treatment of symptoms associated with venolymphatic insufficiency. Official documents specifically list swollen legs as a treatable symptom.

Q: Does Daflon 500 also help with symptoms of restless legs syndrome?

A: The official therapeutic indications explicitly list the treatment of symptoms related to venolymphatic insufficiency, which includes early morning restless legs as an indication.

Q: Is Daflon 500 known to cause tiredness or a general feeling of malaise?

A: A general feeling of discomfort or illness, known as malaise, is listed in the official safety profile as a rare side effect. This means it may affect between 1 and 10 in every 10,000 users.

Q: Are there specific warnings about taking Daflon 500 while breastfeeding?

A: Breastfeeding is not recommended during treatment. This restriction is noted in official documentation due to the absence of data confirming whether the active substance is excreted into human milk.

Q: Are there specific over-the-counter supplements or herbal products that are known to interact with Daflon 500?

A: Official product documentation states that formal interaction studies have not been performed to systematically assess the drug’s potential to interact with other substances. However, no clinically relevant drug interactions have been reported from post-marketing experience with the product, including with supplements or herbal products.

Q: Can Daflon 500 be taken at the same time as Vitamin C?

A: Regulatory information states that no formal interaction studies have been conducted. To date, there have been no reports of clinically relevant interactions with other substances from post-marketing experience.

Q: What is the risk of combining Daflon 500 with other medicines that affect blood flow?

A: The official interaction profile does not include documentation describing additive or synergistic (combined) effects with other medicines that affect blood flow. This means no specific pharmacodynamic interactions are formally defined in the regulatory documents.

Q: Why do people with venous problems often wear compression stockings while taking this medicine?

A: Official labeling states that the management of venous circulation disorders is supported by a healthy lifestyle when combined with the medicine. Official guidance suggests wearing special support stockings and walking to help stimulate blood circulation.

Q: Can lifestyle factors, like diet or exercise, change the effectiveness of Daflon 500?

A: Yes, the official labeling for the treatment of venous circulation disorders suggests that the medicine is supported when it is combined with a healthy lifestyle. This includes practices like regular walking to promote better blood circulation.

Q: Does Daflon 500 interact with aspirin or other common anti-platelet medications?

A: Official documentation states that no formal interaction studies have been performed to assess interaction risks, including with anti-platelet medications like aspirin. However, no clinically relevant drug interactions have been reported from post-marketing experience.

Q: Does Daflon 500 interact with birth control pills?

A: The official interaction profile states that formal interaction studies have not been conducted. As a result, no specific interaction is documented, and no clinically relevant drug interactions have been reported from post-marketing experience, including with hormonal birth control.

Q: What is the average time Daflon 500 remains active in the body?

A: According to the pharmacokinetic properties detailed in the official documentation, the elimination half-life of the active substance (Micronized Purified Flavonoid Fraction) is 11 hours. This half-life refers to the time it takes for half of the drug to be eliminated from the body.

Q: Does Daflon 500 interact with drugs used to treat high cholesterol?

A: The official interaction profile states that no formal studies have been performed to systematically assess potential interaction risks, including with drugs used to treat high cholesterol. No clinically relevant drug interactions have been reported from post-marketing experience.

Q: Does Daflon 500 contain lactose or any common allergens other than the active ingredients?

A: The complete list of inactive ingredients (excipients) used in the tablet formulation is detailed in Section 6.1 of the official product documentation. Patients with known allergies should review this section, as excipients may include common components like lactose, depending on the specific product variant.

Q: Should elderly patients (over 65) use Daflon 500 with special caution?

A: Official product labeling does not require specific dose adjustments for elderly patients. However, due to limited comparative evidence in older adults, official guidance suggests that consultation with a doctor is appropriate for the use of this medicine in the elderly patient subgroup.

Official Storage and Disposal Requirements

This section outlines the regulatory requirements for storing and disposing of Daflon 500 mg tablets, as documented in official government labeling.

Requirement Domain	Official Condition
Temperature Control	Store the medicine at a temperature below 30°C
Packaging Rules	Must be kept in the original carton or outer packaging
Shelf-Life	Do not use after the expiry date shown on the package
Child Safety	Keep the medicine out of the reach and sight of children

For disposal, Daflon 500 mg tablets should not be discarded via wastewater or household waste. Patients are instructed to consult a pharmacist for guidance on how to safely dispose of unused or expired product to ensure environmental protection, as required by regulatory mandates.